AML-508: Phase 1 Study of Mitotic Checkpoint Inhibitor BAL0891 as Monotherapy in Patients With Relapsed or Refractory Acute Myeloid LeukemiaEric J. Feldman, Courtney D. DiNardo, Amer M. Zeidan et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0